[Skip to Navigation]
Sign In
March 19, 2020

Changing the Course of Cancer Care With Greater Precision

Author Affiliations
  • 1Duke Cancer Institute, Duke-Margolis Center for Health Policy, Durham, North Carolina
  • 2Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill
  • 3Division of Hematology/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill
JAMA Oncol. 2020;6(5):634-636. doi:10.1001/jamaoncol.2019.6843

One of us recently received exciting molecular testing results: a patient’s newly diagnosed metastatic colorectal cancer expressed microsatellite instability, a predictive biomarker for immunotherapy. The patient fell into the minority of patients with metastatic colorectal cancer for whom precision oncology truly alters the natural history of disease, potentially prolonging survival by years. Providing biomarker-driven immunotherapy certainly exemplified the tenets of precision oncology.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words